Laboratory Corp of America Holdings (LH)

HEALTH CARE: HEALTH CARE SERVICES
SIC: SERVICES-MEDICAL LABORATORIES

358 S MAIN ST BURLINGTON, NC 27215

Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. Through its unparalleled diagnostics and drug development capabilities, company provides insights and accelerates innovations to improve health and improve lives. With more than 70,000 employees, Labcorp serves clients in more than 100 countries. Labcorp reported revenue of $14 billion in FY2020.

Data as of 2021-06-19 11:06:27 -0400
Market Cap25.421 Billion Shares Outstanding97.7 Million Avg 30-day Volume757.491 Thousand
P/E Ratio9.61844 Dividend Yield EPS26.88
Price/Sales1.66 Debt to Equity2.04 EBITDA4.074 Billion
Price to Book Value2.54 Forward PE11.56 Enterprise Value29.041 Billion
Total Cash1.891 Billion Current Debt3.369 Billion Gross Profit5.824 Billion
BETA0.40196 52-week High/Low280.69 / 155.65 Next Earnings Date2021-07-27 Price to Cash FLow (P/CF) 24.1024
Data provided by IEX Cloud
View SEC Filings from LH instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 31 21 47.62% 15 (0.89%) 10 (0.58%) 50.0%
Funds Holding: 865 888 -2.59% 193 (11.39%) 206 (11.96%) -6.31%
13F shares: 86.635 Million 87.323 Million -0.79% 27.808 Million 26.68 Million 4.23%
% Ownership 88.7658 89.6544 -0.99% 28.4915 27.3917 4.02%
New Positions: 91 143 -36.36% 23 35 -34.29%
Increased Positions 287 308 -6.82% 70 75 -6.67%
Closed Positions 85 42 102.38% 32 13 146.15%
Reduced Positions 320 298 7.38% 77 72 6.94%
Total Calls 590.486 Thousand 481.317 Thousand 22.68% 317.2 Thousand 233.9 Thousand 35.61%
Total Puts 283.355 Thousand 404.728 Thousand -29.99% 184.9 Thousand 246 Thousand -24.84%
PUT/CALL Ratio 0.48 0.84 -42.86% 0.58 1.05 -44.76%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding LH (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding LH BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

9.6 Thousand total shares from 3 transactions

Exercise Derivative Conversion (M)

7.1 Thousand total shares from 2 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

VAN DER VAART SANDRA D EVP, CHIEF LEGAL OFFICER

  • Officer
9,737 2021-06-07 8

KIRCHGRABER PAUL R CEO, COVANCE DRUG DEVELOPMENT

  • Officer
7,844 2021-05-06 8

BELINGARD JEAN-LUC

  • Director
15,569 2021-05-03 3

SCHROEDER MARK S EVP, PRESIDENT-DIAGNOSTICS LAB

  • Officer
5,006 2021-03-30 7

EISENBERG GLENN A CHIEF FINANCIAL OFFICER, EVP

  • Officer
37,433 2021-03-27 5

BERBERIAN LANCE EVP, CIO & CTO

  • Officer
14,186 2021-03-27 4

CAVENEY BRIAN J EVP, PRESIDENT OF DIAGNOSTICS

  • Officer
8,001 2021-03-27 6

WENGEL KATHRYN E

  • Director
0 2021-03-25 3

WILKINSON PETER J SVP, CHIEF ACCOUNTING OFFICER

  • Officer
976 2021-02-12 4

WILLIAMS R SANDERS

  • Director
6,232 2021-02-04 4

ANDERSON KERRII B

  • Director
20,600 2021-02-04 2

NEUPERT PETER M

  • Director
10,982 2021-02-04 2

SCHECHTER ADAM H PRESIDENT & CEO

  • Officer
  • Director
11,288 2021-02-04 3

KONG GARHENG

  • Director
9,438 2021-02-04 2

GILLILAND DWIGHT GARY

  • Director
6,752 2021-02-04 2

PARHAM RICHELLE P

  • Director
6,074 2021-02-04 2

SELTZ JUDITH C EVP, CHRO

  • Officer
915 2021-02-04 2

DAVIS JEFFREY A.

  • Director
1,159 2021-02-04 3

SUMMY AMY B. EVP, CHIEF MARKETING OFFICER

  • Officer
172 2021-02-04 2

KING DAVID P

  • Director
332,096 2020-05-05 0

UTHGENANNT LISA J CHIEF HUMAN RESOURCES OFFICER

  • Officer
4,660 2019-09-04 0

MITTELSTAEDT ROBERT E JR

  • Director
15,515 2019-05-09 0

RATLIFF JOHN D CEO, COVANCE DRUG DEVELOPMENT

  • Officer
17,061 2019-04-03 0

DODSON EDWARD T PRINCIPAL ACCOUNTING OFFICER

  • Officer
13,663 2019-04-01 0

EBERTS F SAMUEL III CHIEF LEGAL OFFICER, SECRETARY

  • Officer
28,823 2019-02-12 0

GARY M. HUFF CEO, LABCORP DIAGNOSTICS

  • Officer
1,850 2018-09-04 0

BOYLE JAMES T. JR. EVP,CEO OF LABCORP DIAGNOSTICS

  • Officer
23,454 2016-03-30 0

KELLER DEBORAH L CEO, COVANCE DRUG DEVELOPMENT

  • Officer
19,754 2016-03-11 0

HERRING JOSEPH L CEO OF COVANCE DRUG DIVISION

  • Officer
No longer subject to file 2015-07-31 0

BRECHER MARK E CMO, LABCORP DIAGNOSTICS

  • Officer
5,511 2015-03-30 0

HAYES WILLIAM B CHIEF FINANCIAL OFFICER, EVP

  • Officer
19,400 2014-06-06 0

LANE WENDY E

  • Director
19,388 2014-05-08 0

RUBENSTEIN ARTHUR H

  • Director
11,772 2014-05-08 0

WEIKEL M KEITH

  • Director
13,958 2014-05-07 0

FONSECA LIDIA CHIEF INFORMATION OFFICER

  • Officer
9,087 2013-03-28 0

COLES N ANTHONY

  • Director
2,584 2013-02-15 0

MAC MAHON THOMAS P

  • Director
32,297 2012-09-06 0

WALTON ANDREW SCOTT EVP

  • Officer
22,298 2012-04-09 0

CONRAD ANDREW J EVP, CHIEF SCIENTIFIC OFFICER

  • Officer
32,641 2011-02-09 0

HARDISON DON M EVP

  • Officer
19,928 2009-12-31 0

SMITH BRADFORD T

  • Director
16,030 2009-02-20 0

LAI GOLDMAN MYLA EVP & CHIEF MEDICAL OFFICER

  • Officer
24,991 2008-11-20 0

HAAS WILLIAM EVP, ESOTERIX BUSINESS

  • Officer
0 2008-05-07 0

MILLER BENJAMIN R EVP, SALES & MARKETING

  • Officer
10,135 2008-03-06 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

VAN DER VAART SANDRA D - Officer EVP, CHIEF LEGAL OFFICER

2021-06-09 14:03:55 -0400 2021-06-07 S 4,500 $266.56 d 5,237 direct yes 0.7022 -0.0386 0.7022 2 -0.2469 3

VAN DER VAART SANDRA D - Officer EVP, CHIEF LEGAL OFFICER

2021-06-09 14:03:55 -0400 2021-06-07 M 4,500 $84.86 a 9,737 direct yes 0.7022 -0.0386 0.7022 2 -0.2469 3

VAN DER VAART SANDRA D - Officer EVP, CHIEF LEGAL OFFICER

2021-06-09 14:03:55 -0400 2021-06-07 M 4,500 d 4,500 direct

KIRCHGRABER PAUL R - Officer CEO, COVANCE DRUG DEVELOPMENT

2021-05-10 08:21:44 -0400 2021-05-06 S 2,500 $276.55 d 7,844 direct -0.3537 -3.5188 0.0 1 -3.5188 6

BELINGARD JEAN-LUC - Director

2021-05-05 10:48:19 -0400 2021-05-03 M 2,600 $98.49 a 18,169 direct 0.677 -1.5568 -5.8036 0.6987 3 -6.3937 27

BELINGARD JEAN-LUC - Director

2021-05-05 10:48:19 -0400 2021-05-03 M 2,600 d 0 direct

BELINGARD JEAN-LUC - Director

2021-05-05 10:48:19 -0400 2021-05-03 S 2,600 $269.16 d 15,569 direct 0.677 -1.5568 -5.8036 0.6987 3 -6.3937 27

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
LABORATORY CRP OF AMER HLDGS LH 2021-06-18 22:15:03 UTC -0.3606 0.4406 3800000
LABORATORY CRP OF AMER HLDGS LH 2021-06-18 21:45:03 UTC -0.3606 0.4406 3800000
LABORATORY CRP OF AMER HLDGS LH 2021-06-18 21:15:03 UTC -0.3606 0.4406 3800000
LABORATORY CRP OF AMER HLDGS LH 2021-06-18 20:45:03 UTC -0.3606 0.4406 3800000
LABORATORY CRP OF AMER HLDGS LH 2021-06-18 20:15:04 UTC -0.3606 0.4406 3800000
LABORATORY CRP OF AMER HLDGS LH 2021-06-18 19:45:03 UTC -0.3606 0.4406 3800000
LABORATORY CRP OF AMER HLDGS LH 2021-06-18 19:15:03 UTC -0.3606 0.4406 3800000
LABORATORY CRP OF AMER HLDGS LH 2021-06-18 18:45:03 UTC -0.3606 0.4406 3800000
LABORATORY CRP OF AMER HLDGS LH 2021-06-18 18:15:02 UTC -0.3606 0.4406 3800000
LABORATORY CRP OF AMER HLDGS LH 2021-06-18 17:45:03 UTC -0.3573 0.3973 3800000
LABORATORY CRP OF AMER HLDGS LH 2021-06-18 17:15:03 UTC -0.3573 0.3973 3800000
LABORATORY CRP OF AMER HLDGS LH 2021-06-18 16:45:03 UTC -0.3573 0.3973 3800000
LABORATORY CRP OF AMER HLDGS LH 2021-06-18 16:15:03 UTC -0.3573 0.3973 3800000
LABORATORY CRP OF AMER HLDGS LH 2021-06-18 15:45:03 UTC -0.3573 0.3973 3800000
LABORATORY CRP OF AMER HLDGS LH 2021-06-18 15:15:03 UTC -0.3573 0.3973 3800000
LABORATORY CRP OF AMER HLDGS LH 2021-06-18 14:45:03 UTC -0.3573 0.3973 3800000
LABORATORY CRP OF AMER HLDGS LH 2021-06-18 14:15:03 UTC -0.3573 0.3973 3800000
LABORATORY CRP OF AMER HLDGS LH 2021-06-18 13:45:03 UTC -0.3573 0.3973 3800000
LABORATORY CRP OF AMER HLDGS LH 2021-06-18 13:15:03 UTC -0.3573 0.3973 3700000
LABORATORY CRP OF AMER HLDGS LH 2021-06-18 12:45:03 UTC -0.3573 0.3973 3700000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Master Neutral Fund LH -12.0 shares, $-2259.24 2020-09-30 N-PORT
GLENMEDE FUND INC- Alternative Risk Premia Portfolio LH -74.0 shares, $-12169.3 2020-04-30 N-PORT
AGF Investments Trust- AGFIQ U.S. Market Neutral Anti-Beta Fund LH -1856.0 shares, $-473335.68 2021-03-31 N-PORT
INVESTMENT MANAGERS SERIES TRUST- AAM HIMCO Global Enhanced Dividend Fund LH -832.0 shares, $-212184.96 2021-03-31 N-PORT
AB CAP FUND, INC.- AB Select US Long/Short Portfolio LH -600.0 shares, $-153018.0 2021-03-31 N-PORT

Elevate your investments